p16 Promoter methylation is a potential predictor of malignant transformation in oral epithelial dysplasia.
Management of the patient with oral epithelial dysplasia depends on the ability to predict malignant transformation. Histologic grading of this condition fails in this regard and is also subject to interpathologist and intrapathologist variability. This study uses longitudinal clinical samples to explore the prognostic value of a previously validated panel of methylation biomarkers in a cohort of patients with histologically proven oral dysplasia. Methylation enrichment pyrosequencing assays were used to provide the sensitivity of traditional methylation-specific PCR with the additional specificity advantages of a subsequent confirmatory sequencing reaction. In 57% (8 of 14) patients with a lesion that transformed to oral squamous cell carcinoma, 26% (26 of 100) of longitudinal samples collected over > or =3 years showed p16 methylation. Only 1% (2 of 184) of samples from 8% of patients (2 of 24) not undergoing malignant transformation within 3 years had p16 methylation. Both of these samples with p16 promoter methylation were the most recently collected and the patients remain under continuing clinical review. Promoter methylation of MGMT, CYGB, and CCNA1 did not correlate with malignant progression. We thus conclude that methylation of the p16 gene promoter shows promise as a predictor for malignant transformation (Fisher's exact, P = 0.002) in a subset of patients.
Hall
Gillian L
GL
Molecular Genetics and Oncology Group, Department of Clinical Dental Sciences, University of Liverpool, Liverpool L69 3GN, United Kingdom.
Shaw
Richard J
RJ
Field
E Anne
EA
Rogers
Simon N
SN
Sutton
David N
DN
Woolgar
Julia A
JA
Lowe
Derek
D
Liloglou
Triantafillos
T
Field
John K
JK
Risk
Janet M
JM
D014408:Biomarkers, Tumor / Q000235:genetics*; D001706:Biopsy; D002471:Cell Transformation, Neoplastic / Q000235:genetics*; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000235:genetics*; D019175:DNA Methylation; D005260:Female; D006801:Humans; D008297:Male; D009062:Mouth Neoplasms / Q000235:genetics* / Q000473:pathology*; D016133:Polymerase Chain Reaction; D011237:Predictive Value of Tests; D011401:Promoter Regions, Genetic / Q000235:genetics; D011446:Prospective Studies; D018709:Statistics, Nonparametric
D014408:Biomarkers, Tumor; D019941:Cyclin-Dependent Kinase Inhibitor p16